Hôpital Montfort Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04243122
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hopital Montfort | Hôpital Montfort | the Association médicale universitaire de l’Hôpital Montfort (AMUHM)

Active Ingredients

Drugs in Phase 2 Trials (2)

acetylsalicylic acid (aspirin) (1 trial)

apixaban (eliquis) (1 trial)

Drugs in Other Trials (1)

heparin (liquaemin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 2)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Thromboembolism (Phase 2)

Venous Thromboembolism (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3